Clofoctol
Подписчиков: 0, рейтинг: 0
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration |
Rectal (suppository) |
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | 98% |
| Metabolism | Hepatic glucuronidation |
| Excretion | Biliary |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.048.739 |
| Chemical and physical data | |
| Formula | C21H26Cl2O |
| Molar mass | 365.34 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Clofoctol is a bacteriostatic antibiotic. It is used in the treatment of respiratory tract and ear, nose and throat infections caused by Gram-positive bacteria. It has been marketed in France till 2005 under the trade name Octofene and in Italy as Gramplus.
It is only functional against Gram-positive bacteria.
It penetrates into human lung tissue.
Apteeus is developing clofoctol as a potential therapy against SARS-CoV-2.
|
Antibacterials: others (J01X)
| |
|---|---|
| Other/ungrouped | |